Fulgent Genetics ( (FLGT) ) has shared an update.
On February 28, 2025, Fulgent Genetics announced its financial results for the fourth quarter and full year of 2024. The company reported a total revenue of $283.5 million for the year, with core revenue growing by 7% year-over-year. Despite a GAAP loss of $42.7 million, Fulgent achieved a non-GAAP income of $15.0 million. The company ended the year with $828.6 million in cash and investments, and its laboratory services exhibited strong growth. Looking ahead, Fulgent projects core revenue of approximately $310 million for 2025, while continuing to advance its clinical pipeline in therapeutic development.
More about Fulgent Genetics
Fulgent Genetics, Inc. is a technology-based company with a well-established laboratory services business and a therapeutic development business. The company’s laboratory services include technical laboratory and testing services, as well as professional interpretation of results by licensed physicians. Fulgent’s therapeutic development focuses on developing drug candidates for treating various cancers using a novel nanoencapsulation and targeted therapy platform.
YTD Price Performance: -14.82%
Average Trading Volume: 256,244
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $479.9M
For an in-depth examination of FLGT stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com